With the growing number of monoclonal antibody therapies for oncologic conditions, timely identification and management of their complications are increasingly important for practitioners. This is a case of a 74-year-old female with primary metastatic melanoma who presented with progressive shortness of breath shortly after initiation of nivolumab. The patient’s endomyocardial biopsy was significant for myocyte damage with inflammatory infiltrate and positive PD-1 staining, indicating myocarditis. The hospital course was complicated by cardiac arrest leading to temporary pacemaker placement, atrial fibrillation with rapid ventricular rate, and concomitant thyroiditis. The patient was started on high-dose (1 mg/kg) steroids and mycophenolate for treatment of myocarditis.
References
[1]
DeVita, V.T., Lawrence, T.S. and Rosenberg, S.A. (2021) DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 11th Ed., Lippincott Williams & Wilkins.
[2]
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. The New England Journal of Medicine, 366, 2443-2454. https://doi.org/10.1056/NEJMoa1200690
[3]
Guo, L., Zhang, H. and Chen, B. (2017) Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 8, 410-416. https://doi.org/10.7150/jca.17144
[4]
Raikhelkar, J. and Uriel, N. (2019) Immune Checkpoint Inhibitor Myocarditis. Current Opinion in Cardiology, 34, 303-306. https://doi.org/10.1097/HCO.0000000000000622
[5]
Schneider, B.J., Naidoo, J., Santomasso, B.D., et al. (2021) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 39, 4073-4126. https://doi.org/10.1200/JCO.21.01440
[6]
Zhang, L., Jones-O’Connor, M., Awadalla, M., Zlotoff, D.A., Thavendiranathan, P., Groarke, J.D., et al. (2019) Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 21, Article No. 32. https://doi.org/10.1007/s11936-019-0731-6
[7]
Johnson, D.B., Balko, J.M., Compton, M.L., Chalkias, S., Gorham, J., Xu, Y., et al. (2016) Fulminant Myocarditis with Combination Immune Checkpoint Blockade. The New England Journal of Medicine, 375, 1749-1755. https://doi.org/10.1056/NEJMoa1609214
[8]
Iyer, P.C., Cabanillas, M.E., Waguespack, S.G., Hu, M.I., Thosani, S., Lavis, V.R., et al. (2018) Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid: Official Journal of the American Thyroid Association, 8, 1243-1251. https://doi.org/10.1089/thy.2018.0116
